LIWANLI Innovation Co Ltd (3054) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of LIWANLI Innovation Co Ltd stock TWD 13.19, price TWD 55.80, that is 76.4% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 18.55 TWD – 90.30 TWD · fair‑value band 11.67 TWD – 15.73 TWD · the 55.80 TWD price screens above the 13.19 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow LIWANLI Innovation Co in your weekly email
Every Wednesday you see whether LIWANLI Innovation Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for males, females, the elderly, and children.
Show moreShow less
Its products include black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, e-soothing powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, drops, and other products.
The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is headquartered in Taipei, Taiwan.
Stock analysis
LIWANLI Innovation Co Ltd (3054) currently trades at 55.80 TWD, while our model-based Fair Value estimate is 13.19 TWD, 76% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 41.15 TWD per share, and 0 of the 10 models we run sit above the 55.80 TWD price.
Bear case: the Dividend Discount group reads lowest at 4.07 TWD, and 10 of the 10 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 11.67 TWD (bear) to 15.73 TWD (bull), the price of 55.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
LIWANLI Innovation Co Ltd reported revenue of 126M TWD in FY2025 versus 47.8M TWD in FY2021, a compound +27.3%/yr. Reported net income was 158M TWD in FY2025, compounding +36.5%/yr from FY2021.
Key figures
Market cap 4.5B TWD (≈ $138M) Micro · P/E ratio 11.0 · P/S ratio 10.9 · EPS (TTM) 5.06 TWD · Dividend yield 1.4% · Net margin 94.5% · Return on equity 34.3% · Return on assets (EBIT) −4.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 80 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 150% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −76%, 3054 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (3.92 TWD to 54.90 TWD). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear11.67 TWDFair Value 13.19 TWDBull15.73 TWD
Price 55.80 TWD · Downside -76.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.65 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+26.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.6%
Start year 2020 (pandemic). Over 10 years: −17.3% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+47.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+46.3%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 46.3% / 16.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → −56%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 26.8%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare LIWANLI Innovation Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−76.4% · Bottom 25%
Profitability
Return on equity (12 months)34.3% · Top 25%
Return on assets13.9% · Top 25%
Net margin (12 months)94.5% · Top 25%
Operating margin (12 months)27.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)537.4% · Top 25%
Dividend yield (12 months)1.4% · Below median
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.0× · Cheapest 25%
P/B4.29× · Priciest 25%
P/S (12 months)10.92× · Priciest 25%
EV/EBITDA59.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 25
PAST (return on equity)100· sector 29
HEALTH (low debt)84· sector 96
DIVIDEND (yield)29· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "LIWANLI Innovation Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/3054
Frequently asked questions
Is LIWANLI Innovation Co Ltd (3054) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 13.19 TWD versus a price of 55.80 TWD, about 76% lower (overvalued).
What is the fair value of 3054?
Our model-based fair value for LIWANLI Innovation Co Ltd is 13.19 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 55.80 TWD.
What is the quality score of 3054?
LIWANLI Innovation Co Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LIWANLI Innovation Co Ltd (3054)?
Our model-based price target is the fair value of 13.19 TWD (as of Nov 8, 2026) from 10 valuation models. Cautious scenario 11.67 TWD, optimistic scenario 15.73 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the LIWANLI Innovation Co Ltd stock forecast for 2026?
Our models put fair value at 13.19 TWD, about 76% lower versus a price of 55.80 TWD (overvalued). Cautious scenario 11.67 TWD, optimistic scenario 15.73 TWD. The calculation is refreshed regularly with new filings.
Does LIWANLI Innovation Co Ltd pay a dividend?
LIWANLI Innovation Co Ltd currently shows a dividend yield of 1.43% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of LIWANLI Innovation Co Ltd (3054) and when is the ex-dividend date?
LIWANLI Innovation Co Ltd pays a dividend of 0.8 TWD per share a year, a dividend yield of 1.4%. The last ex-dividend date was Jun 26, 2026. The payout ratio is 15.8% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of LIWANLI Innovation Co Ltd (3054)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LIWANLI Innovation Co Ltd it is 13.19 TWD per share (as of Nov 8, 2026), against a price of 55.80 TWD. It is the blended result of 10 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is LIWANLI Innovation Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 3054 trades above its calculated fair value: price 55.80 TWD, fair value 13.19 TWD, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3054?
No. The price is what the market pays today (55.80 TWD); the fair value is what the company's own numbers justify (13.19 TWD). For LIWANLI Innovation Co Ltd the two are 42.61 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is LIWANLI Innovation Co Ltd worth?
The market values LIWANLI Innovation Co Ltd at about 4.5B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 55.80 TWD; our models calculate a fair value of 13.19 TWD per share.
What do the bullish and bearish scenarios say about 3054?
Our models span a range for LIWANLI Innovation Co Ltd: cautious scenario 11.67 TWD, base 13.19 TWD, optimistic 15.73 TWD per share (as of Nov 8, 2026, price 55.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 3054?
LIWANLI Innovation Co Ltd trades at a price-to-earnings ratio of 11.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 13.19 TWD is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2018 to 2025), reported earnings: 331.9. Other multiples: P/B 4.3, P/S 10.9, EV/EBITDA 59.2.
How solid is the balance sheet of LIWANLI Innovation Co Ltd (3054)?
Balance-sheet figures for LIWANLI Innovation Co Ltd (as of Nov 8, 2026): return on equity 34.3%, debt of 0.32 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 3054 from its 52-week high?
LIWANLI Innovation Co Ltd trades at 55.80 TWD, about 38% below its 52-week high of 90.30 TWD and 150% above the low of 22.30 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 13.19 TWD is for.
Which stocks are comparable to LIWANLI Innovation Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LIWANLI Innovation Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 55.80 TWD, calculated fair value 13.19 TWD (−76%), Quality Score 60/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3054 calculated?
We run LIWANLI Innovation Co Ltd through 10 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 13.19 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. LIWANLI Innovation Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LIWANLI Innovation Co Ltd (3054)?
The closing price on Nov 9, 2026 was 55.80 TWD. Our model-based fair value is 13.19 TWD, about 76% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LIWANLI Innovation Co Ltd right now?
The price sits above even our optimistic bull case (15.73 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of LIWANLI Innovation Co Ltd
How large is the market capitalisation of LIWANLI Innovation Co Ltd (3054)?
The market capitalisation of LIWANLI Innovation Co Ltd is 4.5B TWD (≈ $138M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LIWANLI Innovation Co Ltd (3054)?
The price-to-sales ratio of LIWANLI Innovation Co Ltd is 10.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LIWANLI Innovation Co Ltd (3054)?
Earnings per share at LIWANLI Innovation Co Ltd are 5.06 TWD (price ÷ EPS = P/E 11.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of LIWANLI Innovation Co Ltd (3054)?
The dividend yield of LIWANLI Innovation Co Ltd is 1.4% (payout 15.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of LIWANLI Innovation Co Ltd (3054)?
The net margin of LIWANLI Innovation Co Ltd is 94.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LIWANLI Innovation Co Ltd (3054)?
The return on equity (ROE) of LIWANLI Innovation Co Ltd is 34.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LIWANLI Innovation Co Ltd (3054)?
On an EBIT basis the return on assets of LIWANLI Innovation Co Ltd is −4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LIWANLI Innovation Co Ltd (3054)?
The operating margin of LIWANLI Innovation Co Ltd is 27.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LIWANLI Innovation Co Ltd (3054)?
Revenue at LIWANLI Innovation Co Ltd is growing +537% versus a year earlier (3y avg +54.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LIWANLI Innovation Co Ltd (3054)?
Earnings per share at LIWANLI Innovation Co Ltd are growing +73.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does LIWANLI Innovation Co Ltd (3054) generate?
The free cash flow of LIWANLI Innovation Co Ltd is −75.8M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LIWANLI Innovation Co Ltd (3054) hold?
LIWANLI Innovation Co Ltd holds more cash than debt, 143M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch LIWANLI Innovation Co Ltd in the live analysis
One click puts LIWANLI Innovation Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026